Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
18 oct. 2024 08h00 HE
|
Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
14 oct. 2024 17h00 HE
|
Helius Medical Technologies, Inc.
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS...
Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study
30 sept. 2024 08h00 HE
|
Helius Medical Technologies, Inc.
-- Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy® in Phase 2 and improvement in DGI scores from Phase 1 to end of treatment at week 14 -- -- Confirms the...
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
16 août 2024 17h00 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced...
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
12 août 2024 16h05 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
06 août 2024 16h36 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
17 juin 2024 07h00 HE
|
Helius Medical Technologies, Inc.
-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S....
Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier
29 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
-- Reimbursement at $23,900, slightly below list price -- -- Represents a significant milestone toward increasing accessibility of PoNS -- NEWTOWN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Helius...
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
23 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
20 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy...